Tantalus Labs announces today that it has received the first Water License issued to a cannabis company in British Columbia. Furnished under the Water Sustainability Act (WSA), the license showcases Tantalus Labs' commitment to effective groundwater resource management and sustainably produced cannabis.

Tantalus Labs utilizes specialized sungrown cultivation technology, natural odour filtration, and an innovative rainwater collection and filtration system. The team is working to establish its facility, SunLab, as an industry leader in reducing the environmental impact of cannabis production.

SunLab was developed to provide plants with the purest natural inputs of water, nutrients, air, and sunlight, at the lowest environmental impact.

Cannabis isn’t the most addictive substance on earth—some argue whether it’s technically addictive at all—but it’s nevertheless true that people sometimes have difficulty reducing or stopping their consumption. Some studies suggest that a small portion of people are prone to what researchers call “cannabis use disorder,” which can interfere with daily life. Now, psychologists seeking to treat the disorder are exploring a new weapon in the fight: virtual reality.

The cannabis industry has a problem…

Culture-based testing is the industry standard for detecting harmful microbes on cannabis flower, but the most widely used culture-based tests have never been validated for use on cannabis.

Our team used genetic sequencing technology to evaluate the accuracy of culture-based microbial tests on cannabis flower, and our findings were peer reviewed and published on F1000.

Our results show that culture-based tests do a poor job of measuring the level of microbial contamination on a cannabis flower, more specifically:

Medicinal Genomics and Courtagen Life Sciences today announced that they will host the 2nd annual CannMed 2017 Personalized Cannabinoid Medicine Conference to be held on April 9-11 in Boston, MA.

Shares in biotech Zelda Therapeutics soared after announced promising results using medical cannabis oil to fight breast cancer.

A short time ago, the shares were up 40% to $0.032.

The initial proof of concept study into the anti-cancer effects of the company’s medical cannabis formulation was conducted by researchers at Complutense University of Madrid. 

“Future studies will examine the potential to significantly increase the anti-cancer effect of traditional chemotherapy drugs and is an exciting opportunity that can not only improve a patient’s quality of life but also potentially extend life expectancy,” says company chairman Harry Karelis. 

What started as a curiosity in Colorado and Washington state in 2012 could have gained the momentum of a juggernaut: marijuana legalization. Now with California and other states passing initiatives to fully legalize recreational marijuana use in November 2016, a new multi-billion-dollar industry could be in the offing. Inventors are already at work on new methods of delivering THC (tetrahydrocannabinol) in stronger and safer doses. And the cultivation sector remains one major area of novel, non-obvious innovation. But with cannabis still on the federal DEA Schedule I of controlled substances what can these idea people do to protect their intellectual property?

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has become one of the most talked about and active cannabis names. This comes as the company was trading at just $.0030 at the end of September before turning into a microcap runner and hitting highs of $.2150 on October 24. Now OWCP has pulled back and looks to be consolidating before making its next move higher. For those that haven’t climbed on board yet, here’s a closer look at OWCP.

The cannabis industry has been trending lower since the election with market sentiment in negative territory following the appointment of Alabama Senator Jeff Sessions as United States Attorney General.

The recent pullback has been associated with weaker-than-average trading volume and we are monitoring this trend on an industry-wide and a company-by-company basis. The lighter trading volume has had a significant affect on cannabis stocks as the average stock spread has expanded (difference between a stock’s buy and sell price) and we continue to monitor this trend closely.

Tel Aviv-based Syqe Medical says its device revolutionizes precise delivery of the drug, already in use in Haifa hospital.

In a world first, Israel’s Teva Pharmaceutical Industries Ltd. and Tel Aviv-based Syqe Medical said they signed a distribution and cooperation agreement to market medical cannabis in an inhaler.

Under the agreement, Teva will be the exclusive marketer and distributor in Israel of an inhaler developed by Syqe Medical for the delivery of medical cannabis. The accord marks the first time that a major global pharma company has agreed to market a medical cannabis product, according to Syqe.

The cannabis industry has grown (pun intended) drastically over the past five years; in 2016 revenue is expected to hit $6.7 billion.  By 2021, the weed industry is expected to have nearly 14,000 companies generating $27 billion, according to consumer market research firm IBISWorld.

The time is green for businesses to jump in and take a hit of those profits. A new startup, cannabis health and wellness company hmbldt, plans to do just that.

Based in California, hmbldt has created a cutting-edge vape pen that delivers a specific dose and formula of the chemicals compounds found in marijuana tailored to suit the individual needs of the user.